Balanced news tone
News Sentiment
PLSE sentiment intelligence
Pulse Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
52 relevant articles
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-10.0% over one week, +7.9% over four weeks, trend active, and materially above fair value.
PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
80/100 classification
One-week reaction
-10.0%
Price reacting lower
Trend fit
Trend active
7.9% over four weeks
Fair value
76.7%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
38
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Pulse Biosciences announced inducement grants to three new employees consistent with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 51,000 stock options and 21,000 restricted stock units, were approved by the Compensation Committee and are intended to align the interests
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 21:41
- Source
- Moomoo
Stock Titan
Direct company coverage
Pulse Biosciences' Three New Employees Get $25.89 Options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 20:05
- Source
- Stock Titan
Stock Traders Daily
Direct company coverage
Liquidity Mapping Around (PLSE) Price Events
This article analyzes Pulse Biosciences Inc (PLSE) using AI models, highlighting weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including a long position strategy with a 72.3:1 risk-reward, a momentum breakout strategy
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 13 Jul 2026 08:41
- Source
- Stock Traders Daily
Ad-hoc-news.de
Direct company coverage
Pulse Biosciences stock stays tied to filings and financing
Pulse Biosciences (PLSE) stock continues to be influenced by its Nasdaq listing, corporate disclosures, and clinical development work rather than commercial scale. As a life-sciences developer, investor focus remains on regulatory progress, financing, and program timing, with spe
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 03 Jul 2026 15:39
- Source
- Ad-hoc-news.de
Sahm
Direct company coverage
Did Warrant Redemptions Just Reframe Pulse Biosciences' (PLSE) Cardiac Ablation Investment Narrative?
Pulse Biosciences recently announced the redemption of remaining common stock warrants from its July 2024 rights offering, a move that could affect its capital structure and long-term positioning in cardiac ablation. This decision, alongside fresh analyst coverage and insider sha
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 18:42
- Source
- Sahm
TradingView
Direct company coverage
Price to earnings forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This page provides financial data for Pulse Biosciences, Inc (NASDAQ: PLSE), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data-focused page from TradingView, indicating that the price-to-earnings forward value is displayed, a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 04:35
- Source
- TradingView
TradingView
Direct company coverage
PLSE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pulse Biosciences, Inc (PLSE) stock, including analyst price targets and predictions for 2027. It details the company's recent stock performance, financial metrics like earnings and revenue, and key company information such as market capitaliz
- Tone
- Positive 73/100
- Event
- Earnings
- Published
- 01 Jul 2026 18:10
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article focuses on the "Price to sales forward" metric for Pulse Biosciences, Inc (NASDAQ: PLSE). It provides a high-level overview of the company's financial data on the TradingView platform, indicating that the market is currently closed. The content is primarily a data pl
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 14:09
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Pulse Biosciences, Inc – NASDAQ:PLSE
The article focuses on the "Price to book forward" financial metric for Pulse Biosciences, Inc. trading under the NASDAQ symbol PLSE. It appears to be a financial data presentation page from TradingView, indicating that the market for PLSE was closed with no trades at the time of
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 04:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Pulse Biosciences, Inc. – FWB:6L8
This article from TradingView briefly presents the enterprise value to revenue forward for Pulse Biosciences, Inc. (FWB:6L8). The content appears to be a stub or a data placeholder, indicating no current trading activity for the specified market. It serves primarily as a navigati
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 15:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article focuses on the enterprise value to EBIT forward for Pulse Biosciences, Inc. (NASDAQ: PLSE). It appears to be a financial data snippet from TradingView, indicating a specific financial metric for the company. The content includes details like the stock market, company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 13:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Pulse Biosciences, Inc – NASDAQ:PLSE
This article provides an overview of Pulse Biosciences, Inc. (NASDAQ: PLSE) with a focus on its enterprise value to revenue forward. It indicates the stock market status on Nasdaq, noting that the market is closed with no trades. The article is primarily a financial snapshot from
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 10:11
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Pulse Biosciences, Inc. – FWB:6L8
This page from TradingView displays financial information for Pulse Biosciences, Inc. (6L8) on the Frankfurt Stock Exchange, specifically focusing on its forward price-to-book ratio. The content also lists various TradingView products, community features, and company information.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 10:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Pulse Biosciences, Inc. – FWB:6L8
This article provides a brief overview of Pulse Biosciences, Inc. (FWB:6L8), focusing on its forward price-to-earnings ratio. It indicates that the company is listed on the Frankfurt Stock Exchange and its market is currently closed with no trades. The content specifically highli
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 00:09
- Source
- TradingView
TradingKey
Direct company coverage
Pulse Biosciences Inc (PLSE) Institutional Confidence
Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 132nd out of 203 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion recently increased by 30.37% quarter-over-quarter to 11.76%. The largest institutio
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 05:39
- Source
- TradingKey
Investing.com
Direct company coverage
Pulse Biosciences stock hits 52-week high at $28.68
Pulse Biosciences (PLSE) stock recently reached a 52-week high of $28.68, reflecting significant investor confidence with an 82.43% increase over the past year and over 100% year-to-date. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 26 Jun 2026 15:10
- Source
- Investing.com
TradingView
Direct company coverage
Pulse Biosciences, Inc. Actuals & Estimates (NASDAQ:PLSE)
This article provides an overview of Pulse Biosciences, Inc. (NASDAQ:PLSE) stock, including its current price, historical performance, and analyst forecasts. It details the company's financial actuals and estimates, such as earnings per share and revenue, and confirms that PLSE d
- Tone
- Positive 67/100
- Event
- Earnings
- Published
- 26 Jun 2026 14:39
- Source
- TradingView
Investing.com Canada
Direct company coverage
Pulse Biosciences stock hits 52-week high at $28.68 By Investing.com
Pulse Biosciences Inc. (PLSE) stock reached a new 52-week high of $28.68, reflecting an 82.43% increase over the past year and over 100% year-to-date. This surge comes despite InvestingPro suggesting the stock may be overvalued, following positive Q1 2026 financial results, Canac
- Tone
- Positive 86/100
- Event
- Earnings
- Published
- 26 Jun 2026 13:41
- Source
- Investing.com Canada
TradingView
Direct company coverage
Pulse Biosciences, Inc. Actuals & Estimates (DUS:6L8)
This article provides financial actuals and analyst estimates for Pulse Biosciences, Inc. (DUS:6L8), including income statement, balance sheet, and cash flow data. It also covers commonly asked questions about the stock, such as its ticker, forecasts, historical prices, earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 02:10
- Source
- TradingView
TradingView
Direct company coverage
6L8 Forecast — Price Target — Prediction for 2027
The article provides a forecast and price target for Pulse Biosciences, Inc. (6L8) stock on the Dusseldorf Stock Exchange. Based on three analyst ratings, the stock has a price target of 26.44 EUR, with a maximum estimate of 27.59 EUR and a minimum of 25.87 EUR. The company's rec
- Tone
- Positive 62/100
- Event
- Analyst action
- Published
- 25 Jun 2026 15:11
- Source
- TradingView
Moomoo
Direct company coverage
Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth
The article discusses Pulse Biosciences (NASDAQ:PLSE) and evaluates its financial position regarding growth investments. It highlights that the company has more cash than debt and positive short-term assets exceeding liabilities, suggesting a strong balance sheet for future growt
- Tone
- Positive 69/100
- Event
- Balance sheet
- Published
- 25 Jun 2026 02:09
- Source
- Moomoo
TradingKey
Direct company coverage
Pulse Biosciences Inc (PLSE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Pulse Biosciences Inc (PLSE), detailing its current price momentum score, support and resistance levels, and various technical indicators. It shows that PLSE's price momentum score is 7.45, with the stock trading between a resistance
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Jun 2026 08:10
- Source
- TradingKey
TradingKey
Direct company coverage
Pulse Biosciences Inc (PLSE) Valuation: PE, PB & Fair Value Analysis
Pulse Biosciences Inc (PLSE) has a current valuation score of 9.27, ranking 26th in the Healthcare Equipment & Supplies industry. The company's P/E ratio is -23.31, reflecting a significant change from its recent high and low. Relevant data for P/B, P/S, and P/CF ratios have not
- Tone
- Negative 31/100
- Event
- Market update
- Published
- 23 Jun 2026 06:41
- Source
- TradingKey
Simply Wall Street
Direct company coverage
Pulse Biosciences (PLSE) Is Up 5.0% After Joining S&P Healthcare Equipment Index Is Sentiment Shifting?
Pulse Biosciences (PLSE) saw its stock rise by 5.0% after being added to the S&P Healthcare Equipment Select Industry Index. This inclusion enhances visibility and comes alongside a strong financial health score and increased institutional ownership. However, the company still fa
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 22 Jun 2026 01:39
- Source
- Simply Wall Street
Stock Traders Daily
Direct company coverage
Understanding Momentum Shifts in (PLSE)
This article analyzes potential momentum shifts in Pulse Biosciences Inc (PLSE), highlighting weak near-term sentiment that could precede changes in mid and long-term outlooks. It details AI-generated trading strategies for different risk profiles, including position, momentum, a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jun 2026 06:09
- Source
- Stock Traders Daily
AD HOC NEWS
Direct company coverage
Pulse Biosciences Stock - weekly review and sector comparison
This article provides a weekly review of Pulse Biosciences (PLSE) stock, focusing on its financial position and comparison within the early-stage medical device and aesthetic-technology sector. It highlights the company's focus on pulsed electric field-based medical technologies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 14:39
- Source
- AD HOC NEWS
Medical Product Outsourcing
Direct company coverage
Pulse Biosciences Strengthens Executive Team
Pulse Biosciences has strengthened its C-Suite by appointing Liane Teplitsky as Chief Operating Officer and expanding Dr. David Kenigsberg's role to full-time Chief Medical Officer. These strategic enhancements aim to accelerate the development and commercialization of the compan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 15:09
- Source
- Medical Product Outsourcing
TradingKey
Direct company coverage
Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides a timeline of dividend and stock split events for Pulse Biosciences Inc (PLSE). It states that the company has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The current stock price, market cap, and other bas
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 17:39
- Source
- TradingKey
TradingKey
Direct company coverage
Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulse Biosciences Inc (PLSE). It details the company's revenue streams by business segment (Systems, Cycle units) and by geographic region (North America, Rest of World) for various fiscal periods. As of the stated update, all reporte
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 16:39
- Source
- TradingKey
Stock Titan
Direct company coverage
Robert W. Duggan receives new PLSE stock option grants (NASDAQ: PLSE)
Robert W. Duggan, a director and 10% owner of Pulse Biosciences (NASDAQ: PLSE), has received two new stock option grants totalling 42,495 shares as part of his equity compensation. These options have an exercise price of $26.89 per share and expire on June 11, 2036. The grants wi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 22:39
- Source
- Stock Titan